PIK3CA and breast cancer: PIK3CA activating mutation induces hyperactivation of the alpha isoform (p110alpha) of phosphatidylinositol-3-kinase (PI3K) and activates the PI3K/AKT/mTOR pathway, which is the most frequently activated pathway in breast cancer and one of the most important mechanisms in endocrine therapy resistance18.